Please assess the completion status of the following clinical trial:

Trial Title: Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of solid tumor, including but not limited to, the following:~  * Stage II-IV germ cell malignancy~ * Small cell lung cancer~ * Recurrent breast cancer OR~* Diagnosis of lymphoma~* About to start a program of antineoplastic chemotherapy for malignant disease that will regularly induce myelosuppression with a risk of temporary severe neutropenia (i.e., neutrophil count less than 500/mm3), but does not routinely require filgrastim (G-CSF) or stem cell support~* Not previously randomized into the Significant trial for a different multicourse chemotherapy program~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Sex:~* Not specified~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Not specified~Renal:~* Creatinine normal OR~* Creatinine clearance greater than 40 mL/min~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception in addition to oral contraceptive pills~* HIV negative~* No epilepsy~* No history of adverse events resulting from fluoroquinolone therapy (e.g., allergy or tendinitis)~* No concurrent use of a sunbed or exposure to strong sunlight~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No other concurrent antibacterial therapy~* No other concurrent prophylactic antibacterial agents including cotrimoxazole prophylaxis against Pneumocystis carinii~* No iron supplements, sucralfate, or mineral antacids 2 hours before or after study medication~* Concurrent entry into other clinical trials allowed

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).